Annual General Meeting of Shareholders 2018
Kedrion’s shareholders approve financial statements for fiscal year 2017, confirm board of directors
Annual Results 2017
Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%
Opening of an antitrust investigation
Released: 31/01/2018 – 17:25 GMTRNS Number: 5463DKedrion S.p.A.31 January 2018 Castelvecchio Pascoli (Lucca, Italy), 31 January 2018 – On 10 January 2018, the Italian antitrust authority “Autorità Garante della Concorrenza e del Mercato” (“AGCM”) opened a formal investigation for potential anticompetitive conduct by Kedrion S.p.A. and Grifols Italia S.p.A.. The investigation concerns the joint
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
First half results 2017
First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%
Result of cash tender offer for Notes due 24 april 2019
The Company hereby announces to accept for purchase Notes validly tendered pursuant to the Offer for a total aggregate principal amount equal to €91,080,000
Launch of new 350 Million Bond and tender offer indicative results
Kedrion successfully completed pricing of new Euro 350 M notes due July 2022 and tender offer for notes due April 2019
Cash Tender Offer for Notes due 24 April 2019
Tender Offer for €300,000,000 4.625 per cent. Notes due 24 April 2019